FILGRASTIM
Light Chain Nephropathy
Brigham and Women's Hospitalprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Light Chain Nephropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Brigham and Women's Hospital | Phase 2 | B |
DARATUMUMAB Brigham and Women's Hospital | D |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →